Your browser doesn't support javascript.
loading
[Current chemotherapy of locally advanced or metastatic bladder tumors]. / Chimiothérapie actuelle des tumeurs de vessie localement avancées ou métastatiques.
Dourthe, L M; Ceccaldi, B; Fournier, R; Houlgatte, A; Merrer, J.
Affiliation
  • Dourthe LM; Service the radiothérapie et d'oncologie médicale, Hôpital d'instruction des armées du Val-de-Grâce, Paris.
Ann Urol (Paris) ; 34(1): 3-8, 2000 Feb.
Article in Fr | MEDLINE | ID: mdl-10763417
Standard chemotherapy of transitional cell carcinoma of the bladder is actually the combination of cisplatine, methothrexate, vinblastine and doxorubicine (MVAC). Although a high response rate, long term survival are rarely observed. More effective agents without toxicity are necessary. Several agents have demonstrated activity alone or in combinations. Combinations regimens use, paclitaxel, gemcitabine and Gallium nitrate, who prove activity alone or in combination with cisplatine or carboplatine, with a response rate of 40 to 70% in patient with visceral localisations. The optimal regimen is not yet determined.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Antineoplastic Agents Limits: Humans Language: Fr Journal: Ann Urol (Paris) Year: 2000 Document type: Article Country of publication: France
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Antineoplastic Agents Limits: Humans Language: Fr Journal: Ann Urol (Paris) Year: 2000 Document type: Article Country of publication: France